Drug Trial Radar · NCT05819359
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
273
Actual
Start
Mar 31, 2023
Primary completion
Apr 2, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- Bial R&D Investments, S.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 35 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Conditions
- Parkinson's Disease
Interventions
BIA 28-6156 10 mgDrug
BIA 28-6156 10 mg, once daily, oral administration.
BIA 28-6156 60 mgDrug
BIA 28-6156 60 mg, once daily, oral administration.
PlaceboDrug
Placebo, once daily, oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from baseline to clinically meaningful progression on motor aspects of experiences of daily living (assessed by MDS-UPDRS Part II score and MDS-UPDRS Part III score)Time frame: From Baseline up to Week 78
Locations
95 sites in 11 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
University of California San Diego
La Jolla, California
Cedars-Sinai
Los Angeles, California
University of Colorado
Aurora, Colorado
Parkinson's Center and Movement Disorders of Boca Raton
Boca Raton, Florida
University of Miami, Dept. of Neurology
Miami, Florida
Renstar Medical Research
Ocala, Florida
Morehouse School of Medicine
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
University of Kentucky
Lexington, Kentucky
University of Maryland Medical Center
Baltimore, Maryland
Baylor University Medical Center
Baltimore, Maryland
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Quest Research Institute, LLC
Farmington Hills, Michigan
Mayo Clinic
Rochester, Minnesota
Struthers Parkinson's Center- East
Saint Paul, Minnesota
Park Nicollet Struther's Parkinson's Center (Struthers Parkinsons Center at HealthPartners)
Saint Paul, Minnesota
Robert Wood Johnson Medical School
New Brunswick, New Jersey
Icahn School of Medicine at Mount Sinai Beth Israel
New York, New York
Weil Cornell Medical Center
New York, New York
Columbia University Medical Center
New York, New York
Northwell Health Physician Partners
New York, New York
Northwell Health
New York, New York
University of Rochester Neurology
Rochester, New York
Cleveland Clinic Foundation
Cleveland, Ohio
University Hospitals Cleveland Medical Center
South Euclid, Ohio
Univerity of Toledo
Toledo, Ohio
Oregon Health and Science University
Portland, Oregon
Parkinson's Disease and Movement Disorders Cente at University of Pennyslvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
MUSC
Charleston, South Carolina
Vanderbilt Medical Center
Nashville, Tennessee
Baylor College of Medicine
Houston, Texas
University of Texas Health Science Center - San Antonio
San Antonio, Texas
Intermountain Healthcare
Salt Lake City, Utah
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.